Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Inhibition of IL-23 mediated inflammation with a novel small molecule inverse agonist of RORgt.

Gauld S, Jacquet S, Gauvin D, Wallace C, Wang Y, McCarthy R, Goess C, Leys L, Huang S, Su Z, Edelmayer R, Wetter J, Salte K, McGaraughty S, Argiriadi M, Honore P, Luccarini JM, Bressac D, Desino K, Breinlinger E, Cusack K, Potin D, Kort M, Masson P.

J Pharmacol Exp Ther. 2019 Aug 2. pii: jpet.119.258046. doi: 10.1124/jpet.119.258046. [Epub ahead of print]

2.

Integrated Psychological Care is Needed, Welcomed and Effective in Ambulatory Inflammatory Bowel Disease Management: Evaluation of a New Initiative.

Lores T, Goess C, Mikocka-Walus A, Collins KL, Burke ALJ, Chur-Hansen A, Delfabbro P, Andrews JM.

J Crohns Colitis. 2019 Jul 25;13(7):819-827. doi: 10.1093/ecco-jcc/jjz026.

PMID:
30721977
3.

Authors' reply: The Association Between Visceral Adipose Tissue and Stricturing Crohn's Disease Behavior, Fecal Calprotectin and Quality of Life.

Bryant RV, Schultz CG, Ooi S, Goess C, Costello SP, Vincent AD, Schoeman S, Lim A, Bartholomeusz FD, Travis SPL, Andrews JM.

Inflamm Bowel Dis. 2019 May 4;25(6):e62-e63. doi: 10.1093/ibd/izy338. No abstract available.

PMID:
30380064
4.

Visceral Adipose Tissue Is Associated With Stricturing Crohn's Disease Behavior, Fecal Calprotectin, and Quality of Life.

Bryant RV, Schultz CG, Ooi S, Goess C, Costello SP, Vincent AD, Schoeman S, Lim A, Bartholomeusz FD, Travis SPL, Andrews JM.

Inflamm Bowel Dis. 2019 Feb 21;25(3):592-600. doi: 10.1093/ibd/izy278.

PMID:
30215805
5.

Obesity in Inflammatory Bowel Disease: Gains in Adiposity despite High Prevalence of Myopenia and Osteopenia.

Bryant RV, Schultz CG, Ooi S, Goess C, Costello SP, Vincent AD, Schoeman SN, Lim A, Bartholomeusz FD, Travis SPL, Andrews JM.

Nutrients. 2018 Sep 1;10(9). pii: E1192. doi: 10.3390/nu10091192.

6.

ABBV-105, a selective and irreversible inhibitor of Bruton's tyrosine kinase, is efficacious in multiple preclinical models of inflammation.

Goess C, Harris CM, Murdock S, McCarthy RW, Sampson E, Twomey R, Mathieu S, Mario R, Perham M, Goedken ER, Long AJ.

Mod Rheumatol. 2019 May;29(3):510-522. doi: 10.1080/14397595.2018.1484269. Epub 2018 Jul 23. Erratum in: Mod Rheumatol. 2019 May;29(3):v.

PMID:
29862859
7.

IL-23, IFN-α, and IFN-β in the vaginal fluid of patients suffering from vulvovaginal candidosis.

Kolben T, Pieper K, Goess C, Degnhardt T, Ditsch N, Weissenbacher T, Weissenbacher ER, Kolben TM.

Clin Exp Obstet Gynecol. 2017;44(1):7-10.

PMID:
29714856
8.

HPV Vaccination: Attitude and Knowledge among German Gynecologists.

Kolben TM, Dannecker C, Baltateanu K, Goess C, Starrach T, Semmlinger A, Ditsch N, Gallwas J, Mahner S, Friese K, Kolben T.

Geburtshilfe Frauenheilkd. 2016 Oct;76(10):1074-1080.

9.

Expression of Sialyl Lewis a, Sialyl Lewis x, Lewis y, Gal-3, Gal-7, STMN1 and p16 in cervical dysplasia.

Kolben TM, Kraft F, Kolben T, Goess C, Semmlinger A, Dannecker C, Schmoeckel E, Mayr D, Sommer NN, Mahner S, Jeschke U.

Future Oncol. 2017 Jan;13(2):145-157. Epub 2016 Sep 20.

PMID:
27646625
10.

Thyroid Hormones and Vitamin D in Patients with Breast Cancer with Mutations in BRCA1 or BRCA2 Genes.

Kolben T, Hary T, Holdt LM, Schwarz TM, Goess C, Wuerstlein R, Gallwas J, Toth B, Weissenbacher T, Jeschke U, Harbeck N, Ditsch N.

Anticancer Res. 2016 Jun;36(6):3185-90.

PMID:
27272846
11.

Impact of guideline-based use of uPA/PAI-1 on patient outcome in intermediate-risk early breast cancer.

Kolben T, Augustin D, Armbrust R, Kolben TM, Degenhardt T, Burgmann M, Goess C, Ditsch N, Kates R, Harbeck N, Wuerstlein R.

Breast Cancer Res Treat. 2016 Jan;155(1):109-15. doi: 10.1007/s10549-015-3653-3. Epub 2015 Dec 7.

PMID:
26643086
12.

Surgical management of ipsilateral breast tumor recurrence.

Kolben T, Schwarz TM, Goess C, Blume C, Degenhardt T, Engel J, Wuerstlein R, Ditsch N, Harbeck N, Kahlert S.

Int J Surg. 2015 Nov;23(Pt A):141-6. doi: 10.1016/j.ijsu.2015.08.084. Epub 2015 Oct 9.

13.

Low muscle mass and sarcopenia: common and predictive of osteopenia in inflammatory bowel disease.

Bryant RV, Ooi S, Schultz CG, Goess C, Grafton R, Hughes J, Lim A, Bartholomeusz FD, Andrews JM.

Aliment Pharmacol Ther. 2015 May;41(9):895-906. doi: 10.1111/apt.13156. Epub 2015 Mar 5.

14.

The Bcl-2 family antagonist ABT-737 significantly inhibits multiple animal models of autoimmunity.

Bardwell PD, Gu J, McCarthy D, Wallace C, Bryant S, Goess C, Mathieu S, Grinnell C, Erickson J, Rosenberg SH, Schwartz AJ, Hugunin M, Tarcsa E, Elmore SW, McRae B, Murtaza A, Wang LC, Ghayur T.

J Immunol. 2009 Jun 15;182(12):7482-9. doi: 10.4049/jimmunol.0802813.

Supplemental Content

Support Center